Related Experiment Videos
[An experimental study of the efficacy of platelet aggregating inhibitor on hepatic metastasis]
Abstract:
To investigate whether OKY-046 (an inhibitor of thromboxane A2 synthetase) and TCV-309 (an antagonist of platelet activating factor) can inhibit VX-2 tumor metastasis, the following studies were performed. Study 1 animal experiment: VX-2 tumors were inoculated and OKY-046 or TCV-309 was administered into the portal vein with or without combination of adriamycin (ADR). The number of tumor nodules on the whole liver surface were counted at three weeks after tumor cells inoculation. The combination of OKY-046 and ADR significantly reduced the number of tumor nodules compared to control and TCV-309. Study 2 in vitro experiment: Human breast cancer cells (MCF-7) overlayed confluently cultured human endothelial cells (HUVEC) in vitro with or without OKY-046 and TCV-309 for 3 days; MCF-7 cells invaded the endothelial cells and built-up colonies. The number of colonies built up were counted. OKY-046 significantly decreased the number of colony formations, but TCV-309 did not. These results suggest that OKY-046 has an inhibitory effect on extravasation of tumor cells.
Insights
OKY-046, a thromboxane A2 synthetase inhibitor, significantly reduced VX-2 tumor metastasis in animal models and inhibited cancer cell invasion in vitro. TCV-309 did not show significant effects on tumor metastasis or invasion.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Metastasis is a complex process involving tumor cell extravasation.
- Thromboxane A2 and platelet-activating factor are implicated in cancer progression.
Purpose of the Study:
- To evaluate the anti-metastatic potential of OKY-046 and TCV-309 against VX-2 tumors.
- To investigate the effect of these agents on cancer cell invasion in vitro.
Main Methods:
- Animal study: VX-2 tumor inoculation in rabbits, administration of OKY-046 or TCV-309 with or without adriamycin, and counting liver tumor nodules.
- In vitro study: Co-culture of human breast cancer cells (MCF-7) with human umbilical vein endothelial cells (HUVEC), treated with OKY-046 or TCV-309, and counting colony formations.
Main Results:
- OKY-046 combined with adriamycin significantly reduced liver tumor nodules in vivo.
- OKY-046 significantly decreased MCF-7 cell colony formation in vitro, while TCV-309 did not.
- TCV-309 showed no significant effect on tumor metastasis or invasion in either study.
Conclusions:
- OKY-046 demonstrates significant anti-metastatic properties against VX-2 tumors.
- OKY-046 inhibits tumor cell extravasation, suggesting a therapeutic role in preventing cancer metastasis.